Advertisement
*
Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.

The world of in-vitro diagnostics is another Midwest success story

I am in a real quandary this week: I have a number of juicy topics I wanted to review with you, including my recent participation in the annual Israel biotech/medical device conference (BIOMED 2006), recent participation in meetings about India and my growing insights into the Indian biotech market, happenings in Japan, and other research that has crossed my transom (including music).

I also started thinking back on why I originally wanted to start writing this column. I realized that during my days at Big Pharma, we had all the money in the world to acquire market research, and were, in fact, spoiled! My life as a biotech entrepreneur made me realize that hard-to-raise money can't be spent on market research in the traditional way, because it is too darn expensive.

In the process (and thanks to the power of the Internet), I learned how to find research sources that would provide me with information about markets that I could include in business plans, PowerPoint presentations, and even press releases!

I started thinking about all the companies and individuals in the same boat, and how it would be great to share this information and insight, but who had the time to do this? Well, at one point, I found I did have the time, and although that time has since evaporated due to multiple work obligations, the discipline of writing these articles and bringing forward information and perspective helps to keep me on top of my game!

When last we met, I was able to give you a perspective on the leading medical device companies of the world, a market which Midwest companies dominate. That market did NOT include another important device-like market: the In Vitro Diagnostics (IVD) market (although it did include the diagnostic imaging market).
Advertisement
In the most recent article, I mentioned that the medical device market (which I thought included the IVD market) probably broke the $200 billion sales revenue mark last year. In fact, according to a market research firm by the name of Health Research International, sales for 2005 topped $220 billion and included four market segments:

• Cardiovascular disease therapies.

• Diagnostic imaging equipment, services, and contrast agents.

• Orthopedic and spinal products.

In-vitro Diagnostics (IVD).

Health research predicts that this market will reach $312 billion in 2010 - only 4 ½ years from now! - or a total growth of 42 percent for this period.

Another publication, Medical Product Outsourcing, in its June 2006 edition, profiles the IVD segment by itself, and while they don't give a total figure for this market, they do list the top 15 companies which are worth analyzing.

Leading In Vitro Diagnostic Companies (2005)
Company/ Country of OriginIVD Sales ($ Millions)Total Company Sales ($ Millions)IVD as % of Total Business
1. Roche Diagnostics (Switzerland - U.S. HQ Indiana)$6,300$27,00023%
2. Abbott Labs (U.S. - Illinois)$3,800$22,30017%
3. Bayer Diagnostics (Germany)$2,500$32,0008%
4. Becton Dickinson(U.S. - New Jersey)$2,500$5,40046%
5. Beckman Coulter (U.S. - California)$1,900$2,40079%
6. Dade-Behring (U.S. - Illinois)$1,700$1,700100%
7. Ortho - Clinical Diagnostics(U.S. - New Jersey)$1,400$50, 5143%
8. bioMerieux(France)$1,200$1,200100%
9. Sysmex (Japan)$716$716100%
10. Bio-Rad Labs(California)$618$1,20052%
11. Arkray(Japan)$470$470100%
12. Diagnostic Products Corp.(California)$399$399100%
13. Olympus America(Japan - U.S. HQ in Pennsylvania)$ 384$8,3005%
14. Cytyc (U.S. - Massachusetts)$362$50871%
15. Gen-Probe(U.S. - California)$306$306100%
TOTAL Top 15 Companies$24,555$154,41316%
Source: Medical Product Outsourcing, June 2006

The top 15 company represented almost $25 billion in sales for 2005, but sales start tailing off significantly with the last company. My guess would be that the total worldwide In Vitro Diagnostics market is somewhere around $27-28 billion for 2005, and according to sources, grew less than double-digit growth for this year. The U.S. once again dominates in this category with 9 of the top 15 companies. Surprisingly, three of the leading companies are Japanese, and only three are European. The top company, Roche Diagnostics, although a Swiss company, has this worldwide division managed not only in the U.S. but here in the Midwest (Indianapolis).

The Midwest has two, and in reality 3 of the top IVD companies (including Roche Diagnostics), with California having another 4 companies, and New Jersey with 2 companies and Massachusetts with one company. These figures don't take into account the high numbers of smaller emerging biotech IVD companies that are growing quickly in the Midwest (Madison, Wisconsin, Chicago, and Minneapolis), California, Boston area and even the Baltimore-Washington, D.C. corridor. In fact, the number of start-up diagnostic companies is growing quickly due to new platform technologies, and the FDA interest in new biomarkers for a variety of diseases.

Diagnostic companies generally do not require the kind of capital that their cousin biotech drug companies need to get to the market place given the lower regulatory hurdles (and time) to achieve an FDA approval. A 510k approval means relatively little if any clinical trials, however with reimbursement a key issue for medical devices and diagnostics, a company is often faced with the question: do we "go" the more extensive PMA (pre-market approval) pathway with the FDA, or "go" with a quicker 501k development pathway. One means quicker time to the market (510k), while the other (PMA) may mean a quicker reimbursement price approval process (for a higher price level), but requires drug-like clinical trials (requiring more time and money) to demonstrate and achieve statistically significant clinical superiority.

The flip side of diagnostics is that a diagnostic "blockbuster" is usually significantly smaller than its pharmaceutical counterpart by tenfold. A diagnostics product "blockbuster" would be a product achieving $100 million or more in annual sales, of which there are very few.

Other key trends in diagnostics:
  • Platform diagnostic machines capable of running multiple tests at once
  • Diagnostic products (tests) that incorporate multiple disease targets
  • Other fluids beyond blood - the most common source of testing; new fluids that are the source of testing include: urine and saliva (the value of these last two is that they are non-invasive: no needle-stick!).
Steve Burrill of Burrill & Co. believes ardently, and I have heard him say this multiple times, that we are moving into a time of high growth of diagnostics given:
  • the need for personalized medicine
  • disease prevention (versus disease treatment)
In the former case, he states that 40% of most drugs don't work (or don't work well) in the chosen patients, and that in the future tests will decide which drug will be used with greater efficacy in a given patient.

A good example is the cancer diagnostic developed by Genentech for its breast drug Herceptin (www.herceptin.com). Genentech's diagnostic test is first administered to a breast cancer patient to see what type of breast cancer they may and to see if this type of cancer will be affected by the very specialized drug which interacts with the Her2neu gene found (or not) in these patients. I think Burrill is not only on the right track, but that his numbers are conservative: probably more like 60% of existing drugs don't work well in target populations.

Another area where this type of diagnostic approach is being used extensively is in organ transplant therapy, where it is critical to know whether a key immunosuppressive drug will have an intended effect or not. A negative could mean a dangerous rejection process until the right drug is found!

The utilization of drug-specific diagnostics alone will drive market growth significantly according to Burrill and I agree with him. The reality is that the drug companies should be seeking out these kinds of diagnostics to help drive a real therapeutic impact of their drug.

Unfortunately most Big Pharma companies don't understand the diagnostic business and are not attracted to what they perceive as "small" product sales. They don't understand the equipment part of this business. Only Abbott, Roche, Bayer, and Johnson & Johnson, of the Big Pharma companies have understood this equation, and all four have historically been involved in the medical device part of the business as much as drugs.

But the coming convergence of drugs, devices, and diagnostics will hasten the need for Big Pharma to pay attention to this important lesson, and get on the diagnostics bandwagon now!

See you soon!

Michael S. Rosen is senior vice president of new business development for Science & Technology Group, which builds bio-parks across the U.S. and currently has bio-parks completed or under development in Cambridge, Baltimore, Chicago, Cleveland, and Denver. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com

The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect the views of The Wisconsin Technology Network, LLC. (WTN). WTN, LLC, accepts no legal liability or responsibility for any claims made or opinions expressed herein.

Comments

Venkata Rao Gali responded 7 years ago: #1

Congratulations Mr.Michael Rosen,

Your well researched and documented report on IVD is of immense help to Biotech/Pharma researchers and analysts like us.
Please keep doing such articles for the benefits of Biotech fraternity.

Best wishes,

Rao from India ( Bangalore)

Mulubrhan Gebreselassie responded 7 years ago: #2

It is very intersting and exiting. It is true there is a lot of potential in gene based test and individaulized therapy.

How ever I believe that people are not confortable to go for it due to lackl of nation wide rules and regulkations of biotechnolgy.

It is high time this issue need to be addressed to encourage consumers that their gene info is secured and will not have negative effects.

Manish Pandey, Mumbai responded 7 years ago: #3

Mr. Rosen,

I feel happy to see my favourite company ROCHE Diagnostics topping your table. Also it is amongst few selected companies like Ortho and Abbott who utilise their synergies in Pharmaceuticals and Diagnostics. This is very useful as they can understand not only treatment part of the disease but also diagnostic aspect also. Other big pharma company should look into this model. Next wave in Diagnostics will be that which takes into account role of Biotech / Info Tech / NanoTech.

Bye
Manish Pandey
Mumbai
India

Neelam Ramteke responded 7 years ago: #4

Mr. Rosen:
It's a very interesting article for all the biotech healthcare industry. We'll as the time pass be to develop more sophisitcated medical devices for the well-being of the mankind.

Pradeep Joshi Yahraj Biotech Mumbai responded 7 years ago: #5

Dear Sir,

Thanks for sharing such valuable information on this site. It is really a time where we need to look for in-depth persepective.

Viral M Desai responded 7 years ago: #6

Dear sir,
Thanks for sharing such valuable information not only for the biotechnology industry but for the health care industry as a whole. Your article is of great use to market researchers like me. Keep informing us about such details in future.

Regards
Viral M Desai

Subhasis Banerjee responded 5 years ago: #7

Many thanks. Learned a lot.
I very much agree with you that IVD driven to understand the efficacy of a specic line of therapy would be the most important area of R&D

Lakshminarayanan responded 4 years ago: #8

Dear Mr.Rosen,

Congragulation to you for a nice article. This will be good knowledge sharing and eye opening information. Keep doing such things.

Sincerely Yours,

Lakshminarayanan

-Add Your Comment

Name:
E-mail:

Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and are not immediately posted. Your email address will not be posted.

WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact edit@wistechnology.com.

WTN InGroup
Advertisement
Madison High Tech Directory

-More Stories

WTN Media Presents